Systemic cyclosporine administration for high-risk corneal transplantation

Systemic cyclosporine administration for high-risk corneal transplantation - Cyclosporine for high-risk corneal transplantation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003767

Enrollment

Registered

2010-06-20

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High-risk corneal transplantation

Interventions

Systemic cyclosporine administration. Cyclosporine is used for at least 6 months following corneal transplantation with C2 blood level with approximately 800 ng/ml Topical corticosteroids. 0.1% dexa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Recipients of high-risk corneal transplantation which is defined as one of the following conditions; 1) Presence of deep corneal neovascularization with more than one quadrant 2) History of previous penetrating keratoplasty (regrafting)

Exclusion criteria

Exclusion criteria: 1) poorly controlled diabetes mellitus 2) poorly controlled hypertension 3) abnormal kidney function 4) abnormal liver function 5) active ocular infection 6) active systemic infectious diseases 7) uncontrollable ocular hypertension 8) severe corneal limbal dysfunction

Design outcomes

Primary

Measure	Time frame
Incidence of graft rejection following corneal transplantation	—

Secondary

Measure	Time frame
Incidence and severity of local or systemic complications	—

Countries

Japan

Contacts

Public ContactJun Shimazaki

Tokyo Dental College, Ichikawa General Hospital Department of Ophthalmology

jun@eyebank.or.jp0473-22-0151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026